BioSignia scientists author second publication

BioSignia’s Chief Science Officer, Guizhou Hu, MD, PhD and our Senior Vice President of Science, Ashlee Duncan, MS, PhD were the authors of a manuscript published in the most recent issue of the Journal of Insurance Medicine. The research focuses on the relationship between selected clinical laboratory tests and all-cause mortality, and an abstract of the work follows:

Objective. – Evaluate the association of selected laboratory tests, including liver function, kidney function, bilirubin, and albumin, with all-cause mortality.

Method. – Associations between several laboratory tests and mortality were assessed in two longitudinal datasets: (1) the Third National Health and Nutritional Examination Survey (NHANES III) with 4,610 deaths during the 240,428 person-year follow-up; and (2) a life insurance dataset containing historical life insurance policies issued as standard and better risk class, with 837 death claims generated during the approximate 1.4 million person-years of follow up. A Cox proportional hazard model was used to compute the hazard ratio of each selected laboratory test while adjusting for age, gender, and other health conditions. Separate analyses were conducted for laboratory results within and beyond the respective normal clinical range.

Results. – When outside the normal clinical range, the results of several selected laboratory tests were associated with higher mortality, as indicated by a hazard ratio greater than 1. Comparisons of hazard ratios when laboratory results were within the normal range demonstrated that blood albumin and blood urea nitrogen (BUN) were both negatively associated with mortality and alkaline phosphatase (AP) was positively association with mortality. The associations were shown to be independent and were consistent in two datasets.

Conclusion. – Although abnormal laboratory results are significant predictors of higher mortality, when results fall within the normal clinical range, only three tests – albumin, AP, and BUN – provided mortality differentiation. These findings support the utilization of the actual, continuous value from albumin, AP, and BUN tests to evaluate mortality during underwriting, even when these results are categorized as clinically normal. Furthermore, the results provide an insightful perspective for evaluating the utility of recently developed, laboratory test-based underwriting tools.

Full citation: Hu G and Duncan AW. Associations between selected laboratory tests and all-cause mortality. J Insur Med 2013;43:208–220.

BioSignia, Inc. • 401 Harrison Oaks Blvd., Suite 120 • Cary, NC 27513 • (919) 933-2021 • (888) 324-6627